These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 913025

  • 21. Phenylbutazone and oxyphenbutazone distribution into tissue fluids in the horse.
    Lees P, Taylor JB, Higgins AJ, Sharma SC.
    J Vet Pharmacol Ther; 1986 Jun; 9(2):204-12. PubMed ID: 3723663
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys.
    Mealey KL, Matthews NS, Peck KE, Ray AC, Taylor TS.
    Am J Vet Res; 1997 Jan; 58(1):53-5. PubMed ID: 8989496
    [Abstract] [Full Text] [Related]

  • 25. Simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography.
    Pound NJ, Sears RW.
    J Pharm Sci; 1975 Feb; 64(2):284-7. PubMed ID: 1127584
    [Abstract] [Full Text] [Related]

  • 26. Individual differences in the plasma half-lives of lipid soluble drugs in man.
    Davies DS, Thorgeirsson SS.
    Acta Pharmacol Toxicol (Copenh); 1971 Feb; 29 Suppl 3():181-90. PubMed ID: 5316400
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Determination of bumadizone, phenylbutazone and oxyphenbutazone in human plasma by high-performance liquid chromatography (author's transl)].
    Spahn H, Mutschler E.
    Arzneimittelforschung; 1981 Feb; 31(3):495-9. PubMed ID: 6894379
    [Abstract] [Full Text] [Related]

  • 31. Plasma half-life of phenylbutazone in patients with impaired liver function.
    Hvidberg EF, Andreasen PB, Ranek L.
    Clin Pharmacol Ther; 1974 Feb; 15(2):171-7. PubMed ID: 4855829
    [No Abstract] [Full Text] [Related]

  • 32. Letter: Fixed skin eruption caused by oxyphenbutazone with cross-reactivity to phenylbutazone.
    Pandhi RK, Dedi TR.
    Arch Dermatol; 1975 Jan; 111(1):131. PubMed ID: 1119818
    [No Abstract] [Full Text] [Related]

  • 33. [Effect of phenylbutazone and oxyphenbutazone on gastric acid production].
    Hemmati A.
    Arzneimittelforschung; 1969 Jul; 19(7):1130-2. PubMed ID: 5394515
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys.
    Matthews NS, Peck KE, Taylor TS, Mealey KL.
    Am J Vet Res; 2001 May; 62(5):673-5. PubMed ID: 11341383
    [Abstract] [Full Text] [Related]

  • 36. [On the thyrostatic effect of phenylbutazone and oxyphenbutazone under the influence of triiodothyronine].
    Eger W, Fernholz J.
    Med Pharmacol Exp Int J Exp Med; 1965 May; 13(1):17-23. PubMed ID: 5898618
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Influence of tobacco on the serum levels and pharmacokinetics of phenylbutazone and oxyphenbutazone].
    Queneau P, Ollagnier M, Decousus H, Perpoint B, Brazier JL, Faucon L.
    Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):293-7. PubMed ID: 6879097
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.